Considering that Zogenix stock price was $6 a share in 2011 three years prior to the recent FDA Approval of Zohydro, the company and the product is currently being neglected and the stock price is languishing.
A North Carolina drug maker plans to test its experimental antiviral drug in patients who have Ebola, after getting authorization from regulators at the Food and Drug Administration.
Chimerix Inc. said Thursday that it has received FDA clearance to proceed with a trial examining the safety and effectiveness of its brincidofovir tablets in patients who have the virus. The company said in a statement that the drug is available for immediate use in testing.
With the FDA's permission, the Durham, North Carolina, drugmaker previously made the drug available to the first Ebola patient diagnosed in the U.S., who died in Dallas last week. Chimerix did not immediately return requests for comment.
The FDA does not publicly confirm when it has granted companies permission to begin testing. The agency has not approved any drugs as safe and effective in treating Ebola.
Brincidofovir is an antiviral drug being developed to treat several types of viruses, including one that infects patients undergoing bone marrow transplants. Chimerix is working with the U.S. Department of Defense on developing the drug as a treatment against smallpox. Laboratory tests suggested it may also work against Ebola.
Chimerix's drug is one of three experimental medications known to have been used on Ebola patients during the current outbreak. The other two are:
ZMapp from San Diego-based Mapp Pharmaceuticals, which was developed specifically as an Ebola treatment. It is a cocktail of antibodies engineered to recognize the virus and bind to infected cells. Supplies are exhausted, though federal officials say work is underway to produce more.
The TKM-Ebola injection, by Tekmira Pharmaceuticals of Canada, works by blocking genes that help the Ebola virus reproduce and spread. It has been used in at least one patient and is said to be in limited supply.
Under pressure to select an Ebola "czar" to lead the U.S. response against the disease, President Barack Obama conceded Thursday it "may be appropriate for me to appoint an additional person" to head the administration effort.
At the time of the article at $4.69 a share that equates to $6.50 a share.
Deval Patrick Says He Might Run for President
Patrick, who's nearing the end of his eight-year run as governor, made the comments in an interview with WCVB.
WCVB reported Patrick made the comments during a taping of its show “ On the Record.”
“There are a lot of people who have asked me to think about (running for president),” Patrick said. “It’s a huge decision, not just for me but for my family.”
When asked if he would indeed run, Patrick said, “Maybe, but not right away.”
Patrick, 58, is nearing the end of his second term as governor. He’s not running for re-election. Massachusetts does not have term limits for the governor’s office.
Patrick is a former civil rights lawyer at the Department of Justice and served as legal counsel for companies like Coca-Cola and Texaco. He has a close relationship with President Obama.
In 2011, Patrick told the State House News Service he’d consider running a company when his run as governor was up.
After he was elected governor in 2006, Patrick said he considered resigning because of the toll the campaign took on his wife, Diane, who was treated for depression.
Before the Reverse Split if a Phase III Approval had taken place, the stock could have possibly jumped from $0.40 a share up into the $1's, $2's or $3's. So stockholders should not be surprised if the price per share in its current valuation was to skyrocket with FDA Approval.
Of this I am fairly sure and the response may not happen all in one day with the news, but during the following weeks. Even $50 or $100 a share eventually would not surprise me and those of us who have held the stock prior to the Reverse Split.
I stepped away from the computer in the later part of the trading day. When I returned I was pleased to see a considerable lift encouraged by the two largest trades of the day which occurred at the close. Wishing an enjoyable weekend to all the ZIOPHARM Oncology Longs.